Credits Available: 5.0 AMA PRA Category 1 Credits

Description: The proposed activities will inform clinicians of recent evidence from clinical trials on the efficacy and safety of TROP2-directed antibody-drug conjugates (ADCs) in patients with progressive NSCLC, allowing them to quickly integrate new treatments into their practice when they become available. Clinicians will be updated on HER2 genomic alterations and apply appropriate testing methodologies per the National Comprehensive Cancer Network (NCCN) guidelines for NSCLC. Furthermore, participants will receive education on the successful management of NSCLC, including managing brain metastases, optimal HER2-targeted ADC dosing, and monitoring approaches for treatment-related adverse events (AEs). Finally, the proposed activities aim to educate participants on the importance of targeting HER3 and using HER3-directed ADCs in the management of NSCLC. The initiative will also provide information on the efficacy and safety of these ADCs based on clinical trial data, as well as strategies for recognizing and minimizing treatment-related AEs to enhance therapy adherence and improve patient outcomes.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse Practitioner, Physician Assistant
Target Specialties: Oncology

Frank Weinberg

University of Illinois Chicago

Dr. Weinberg is currently an Assistant Professor in the Division of Hematology and Oncology at UIC and Director of the thoracic oncology program. He is a physician scientist dedicated to clinical care of patients and translation research. He received his PhD at Northwestern University in the field of cancer biology and performed seminal work elucidating the importance of mitochondrial metabolism in lung cancer tumorigenesis. He then completed his MD at University of Illinois College of Medicine followed by residency and fellowship in hematology and oncology at University of Michigan. He is dedicated to the discovery of biomarkers in the underrepresented, high risk lung cancer screening population as well as in patients with lung cancer at UI Health through a reverse translational science approach. Since coming to UIC he has developed a passion for correlating clinical health disparities with biology in the hopes that this will lead to more efficacious and novel therapies for underrepresented individuals. He also has his own independent research lab focused on elucidating immunometabolic pathways that are prognostic and predicitive in high risk individuals and patients with lung cancer, patients with early stage lung cancer as well as patients with lung cancer who develop resistance to immunotherapy and other therapeutic targets.